Alivus Life Sciences quarterly results

Q2 FY27 · Jul–Sep 2026

₹ crore	Q2 FY27	Q2 FY26	Change
Revenue	682	588	+16.0%
EBITDA	265	179	+48.0%
EBITDA margin	38.9%	30.5%	+8.4 pts
Profit before tax	262	174	+50.4%
Net profit	197	130	+51.3%
EPS	₹16.02	₹10.60	+51.1%

Every quarter

₹ crore except per share

Tap a line for its trend	Q2 FY27Sep 2026	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023

Expenses
	682	640	689	673	588	602	650	642	507	589	537	573
	19.9	22.4	22.8	13.9	14.7	9.0	10.1	10.5	8.5	5.5	3.1	1.7
	702	663	712	687	603	611	660	652	515	594	540	574
	299	253	229	276	289	269	280	288	239	246	248	243
	−56.4	1.9	42.1	0.1	−40.0	1.4	2.1	−2.3	−13.9	41.4	−9.1	−0.9
	69.6	68.2	78.1	66.4	66.4	61.6	66.7	65.7	62.4	56.8	72.3	71.1
	1.3	1.3	1.3	1.5	1.3	1.3	1.3	0.5	0.3	0.4	0.4	0.4
	21.8	20.6	20.2	19.7	18.4	17.1	16.0	15.2	15.1	14.4	14.5	13.2
	104	105	126	98.8	93.5	97.6	102	101	84.9	84.5	84.2	87.0
	440	451	496	463	429	448	468	467	388	444	410	414
	265	212	215	231	179	172	198	190	134	159	141	173
	243	191	194	212	161	155	182	175	119	145	127	159
Profit
	262	212	216	224	174	163	191	185	127	150	130	161
	0.0	0.0	0.0	−25.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	262	212	216	198	174	163	191	185	127	150	130	161
	60.6	50.3	51.1	53.9	40.0	38.9	47.9	46.8	30.2	37.5	31.1	38.9
	4.6	1.9	2.0	−5.8	4.2	2.5	1.5	1.4	1.9	1.2	0.7	3.1
	65.2	52.1	53.1	48.1	44.1	41.4	49.4	48.2	32.1	38.8	31.7	41.9
	197	160	163	150	130	122	142	137	95.3	111	97.9	119
	197	160	163	150	130	122	142	137	95.3	111	97.9	119
	0.9	0.3	1.3	−0.0	0.3	−0.3	−0.2	−0.4	−0.5	−0.2	0.1	−3.5
	198	160	164	150	130	121	142	137	94.8	111	98.1	115
Per share
	₹16.02	₹13.04	₹13.23	₹12.25	₹10.60	₹9.91	₹11.57	₹11.18	₹7.78	₹9.10	₹7.99	₹9.69
	₹15.98	₹13.01	₹13.22	₹12.22	₹10.58	₹9.88	₹11.55	₹11.14	₹7.75	₹9.08	₹7.97	₹9.67
Other comprehensive income — detail
	0.9	0.3	1.3	−0.0	0.3	−0.3	−0.2	—	—	—	—	—
	1.2	0.4	1.7	−0.0	0.4	−0.4	−0.2	−0.5	−0.7	−0.2	−0.2	−4.4
	0.3	0.1	0.4	−0.0	0.1	−0.1	−0.1	—	—	—	—	—
	—	—	—	—	—	—	—	−0.1	−0.2	−0.1	−0.4	−0.8
Per share — as-filed variants
	₹16.02	₹13.04	₹13.23	₹12.25	₹10.60	₹9.91	₹11.57	₹11.18	₹7.78	₹9.10	₹7.99	₹9.69
	₹15.98	₹13.01	₹13.22	₹12.22	₹10.58	₹9.88	₹11.55	₹11.14	₹7.75	₹9.08	₹7.97	₹9.67
Regulatory disclosures — filed alongside, not part of the P&L
	—	—	1.1	—	0.1	—	463	—	—	—	—	—
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	439	385	418	396	339	331	367	357	282	301	298	331
	64.4%	60.2%	60.7%	58.9%	57.7%	55.1%	56.5%	55.6%	55.6%	51.1%	55.5%	57.7%
Adjusted (ex-exceptional items) — derived
	262	212	216	224	174	163	191	185	127	150	130	161
	0.0	0.0	0.0	−25.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	197	160	163	170	130	122	142	137	95.3	111	97.9	119
	₹16.02	₹13.04	₹13.23	₹13.83	₹10.60	₹9.91	₹11.57	₹11.18	₹7.78	₹9.10	₹7.99	₹9.69

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ALIVUS₹1,397.40

Alivus Life Sciences Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersDIVISLAB AARTIDRUGS AKUMS AGARWALEYE APLLTD ADVENZYMES AARTIPHARM CORONA

View

In ₹ Crore except Per Share 3 Months Ending	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026	Q2 FY27 30/09/2026
Revenue from Operations	572.8	536.6	588.6	506.9	641.8	649.5	601.8	588.0	672.9	689.1	640.4	682.0
Other Income	1.7	3.1	5.5	8.5	10.5	10.1	9.0	14.7	13.9	22.8	22.4	19.9
Total Income	574.5	539.7	594.1	515.4	652.3	659.6	610.8	602.7	686.8	711.9	662.8	701.9
Expenses
+ Cost of Materials Consumed	243.1	247.8	246.4	239.1	287.6	280.5	269.0	289.0	276.4	228.7	253.1	299.2
+ Changes in Inventories	-0.9	-9.1	41.4	-13.9	-2.3	2.1	1.4	-40.0	0.1	42.1	1.9	-56.4
+ Employee Benefit Expense	71.1	72.3	56.8	62.4	65.7	66.7	61.6	66.4	66.4	78.1	68.2	69.6
+ Finance Costs	0.4	0.4	0.4	0.3	0.5	1.3	1.3	1.3	1.5	1.3	1.3	1.3
+ Depreciation & Amortisation	13.2	14.5	14.4	15.1	15.2	16.0	17.1	18.4	19.7	20.2	20.6	21.8
+ Other Expenses	87.0	84.2	84.5	84.9	100.6	101.8	97.6	93.5	98.8	125.6	105.4	104.3
Total Expenses	413.8	410.0	443.9	388.0	467.2	468.3	447.9	428.6	462.8	496.1	450.6	439.9
EBITDA	172.6	141.4	159.5	134.4	190.3	198.4	172.3	179.2	231.3	214.5	211.7	265.2
EBIT	159.4	126.9	145.1	119.3	175.1	182.5	155.2	160.7	211.6	194.3	191.1	243.4
Profit
PBT before Exceptional Items	160.7	129.7	150.2	127.5	185.1	191.3	163.0	174.1	224.0	215.8	212.2	262.0
+ Exceptional Items	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-25.7	0.0	0.0	0.0
Pretax Income	160.7	129.7	150.2	127.5	185.1	191.3	163.0	174.1	198.4	215.8	212.2	262.0
+ Current Tax	38.9	31.1	37.5	30.2	46.8	47.9	38.9	40.0	53.9	51.1	50.3	60.6
+ Deferred Tax	3.1	0.7	1.2	1.9	1.4	1.5	2.5	4.2	-5.8	2.0	1.9	4.6
Tax Expense	41.9	31.7	38.8	32.1	48.2	49.4	41.4	44.1	48.1	53.1	52.1	65.2
Net Income	118.8	97.9	111.5	95.3	137.0	141.9	121.5	130.0	150.3	162.7	160.1	196.7
+ Net Income — Continuing Ops	118.8	97.9	111.5	95.3	137.0	141.9	121.5	130.0	150.3	162.7	160.1	196.7
+ Other Comprehensive Income	-3.5	0.1	-0.2	-0.5	-0.4	-0.2	-0.3	0.3	-0.0	1.3	0.3	0.9
Total Comprehensive Income	115.2	98.1	111.3	94.8	136.6	141.7	121.2	130.3	150.2	163.9	160.4	197.6
Per Share
Basic EPS	9.69	7.99	9.10	7.78	11.18	11.57	9.91	10.60	12.25	13.23	13.04	16.02
Diluted EPS	9.67	7.97	9.08	7.75	11.14	11.55	9.88	10.58	12.22	13.22	13.01	15.98
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	-0.2	-0.3	0.3	-0.0	1.3	0.3	0.9
+ Items NOT to be Reclassified to P&L	-4.4	-0.2	-0.2	-0.7	-0.5	-0.2	-0.4	0.4	-0.0	1.7	0.4	1.2
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	-0.1	-0.1	0.1	-0.0	0.4	0.1	0.3
+ Tax on Items NOT to be Reclassified — alt tag	-0.8	-0.4	-0.1	-0.2	-0.1	—	—	—	—	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	9.69	7.99	9.10	7.78	11.18	11.57	9.91	10.60	12.25	13.23	13.04	16.02
Diluted EPS — Continuing Operations	9.67	7.97	9.08	7.75	11.14	11.55	9.88	10.58	12.22	13.22	13.01	15.98
Regulatory Disclosures — filed alongside, not part of the P&L
Related-party Transactions — During the Period	—	—	—	—	—	463.4	—	0.1	—	1.1	—	—
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	330.6	297.9	300.8	281.7	356.6	366.9	331.5	339.1	396.5	418.3	385.4	439.1
Gross Margin %	57.72	55.52	51.11	55.57	55.55	56.49	55.07	57.67	58.92	60.70	60.18	64.39
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	160.7	129.7	150.2	127.5	185.1	191.3	163.0	174.1	224.0	215.8	212.2	262.0
− Exceptional Items (reconciliation)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-25.7	0.0	0.0	0.0
Net Income Adj (tax-effected)	118.8	97.9	111.5	95.3	137.0	141.9	121.5	130.0	169.7	162.7	160.1	196.7
EPS Adj	9.69	7.99	9.10	7.78	11.18	11.57	9.91	10.60	13.83	13.23	13.04	16.02
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Paid Up Equity Capital	24.5	24.5	24.5	24.5	24.5	24.5	24.5	24.5	24.5	24.5	24.5	24.6

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q2 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Alivus Life Sciences Q2 FY27 results (July–September 2026)

Filed with NSE on Thursday, 29 October 2026 at 7:21 pm IST

Alivus Life Sciences (NSE: ALIVUS) reported its Q2 FY27 results (July–September 2026) on Thursday, 29 October 2026 at 7:21 pm IST. Consolidated net profit was ₹197 crore, up 51.3% from ₹130 crore in Q2 FY26 and up 22.9% from ₹160 crore in Q1 FY27. Revenue from operations was ₹682 crore, up 16.0% year on year and up 6.5% from the previous quarter.

Q2 FY26 results (a year earlier): 6 November 2025
Q3 FY27 results due by: 14 February 2027

Q2 FY27 at a glance · consolidated

Net profit: ₹197 Cr+51.3% vs Q2 FY26+22.9% vs Q1 FY27
Revenue from operations: ₹682 Cr+16.0% vs Q2 FY26+6.5% vs Q1 FY27
Operating margin (EBIT): 35.7%+8.3 pts vs Q2 FY26+5.8 pts vs Q1 FY27EBIT ₹243 Cr
EBITDA: ₹265 Cr+48.0% vs Q2 FY26+25.3% vs Q1 FY27margin 38.9%
Earnings per share (basic): ₹16.02+51.1% vs Q2 FY26+22.9% vs Q1 FY27
Net profit margin: 28.8%+6.7 pts vs Q2 FY26+3.9 pts vs Q1 FY27

Questions

What was Alivus Life Sciences' net profit in Q2 FY27?

Consolidated net profit was ₹197 crore, up 51.3% from ₹130 crore in Q2 FY26 and up 22.9% from ₹160 crore in Q1 FY27.

What was Alivus Life Sciences' revenue in Q2 FY27?

Revenue from operations was ₹682 crore, up 16.0% year on year and up 6.5% from the previous quarter.

What was Alivus Life Sciences' net profit in FY24?

Consolidated net profit was ₹471 crore in FY24 (April 2023–March 2024), up 0.8% from ₹467 crore in FY23. It was ₹419 crore in FY22.

How were Alivus Life Sciences' Q2 FY27 results?

Both grew from a year earlier: net profit was up 51.3% at ₹197 crore and revenue was up 16.0% at ₹682 crore. The operating margin was 35.7%, up 8.3 percentage points from 27.3% a year earlier. Against Q1 FY27, net profit was up 22.9% and revenue up 6.5%.

What was Alivus Life Sciences' operating margin in Q2 FY27?

Operating profit (EBIT — revenue less operating expenses, before finance costs and other income) was ₹243 crore, a margin of 35.7%, against 29.8% in Q1 FY27 and 27.3% in Q2 FY26. EBITDA was ₹265 crore, 38.9% of revenue.

What was Alivus Life Sciences' net profit in the first half of FY27?

Consolidated net profit for the first half of FY27 (April–September 2026) was ₹357 crore, up 41.8% from ₹252 crore in the same months a year earlier. Revenue from operations was ₹1,322 crore, up 11.1%.

What was Alivus Life Sciences' EPS in Q2 FY27?

Basic earnings per share were ₹16.02, against ₹10.60 in Q2 FY26.

What was Alivus Life Sciences' revenue in FY24?

Revenue from operations was ₹2,283 crore in FY24 (April 2023–March 2024), up 5.6% from ₹2,161 crore in FY23. It was ₹2,123 crore in FY22.

When did Alivus Life Sciences announce its Q2 FY27 results?

On Thursday, 29 October 2026 at 7:21 pm IST, in its results filing to the stock exchanges. A year earlier it reported Q2 FY26 on 6 November 2025.

What is Alivus Life Sciences' net profit margin?

Alivus Life Sciences' net profit margin was 28.8% in Q2 FY27 (net profit as a share of revenue from operations), against 22.1% in Q2 FY26 (up 6.7 percentage points). For FY24 as a whole it was 20.6%.

How has Alivus Life Sciences' profit changed over the last four quarters?

Net profit by quarter: ₹150 crore in Q3 FY26, ₹163 crore in Q4 FY26, ₹160 crore in Q1 FY27 and ₹197 crore in Q2 FY27. That is ₹670 crore over the four quarters, up 26.3% from ₹530 crore in the four quarters before. Revenue from operations: ₹673 crore, ₹689 crore, ₹640 crore and ₹682 crore.

When will Alivus Life Sciences announce its Q3 FY27 results?

Q3 FY27 covers October–December 2026. Listed companies must publish quarterly results within 45 days of the quarter's end (SEBI listing rules, Regulation 33), so the results are due by 14 February 2027. The company tells the exchanges the date of the board meeting at least two working days before it.

Where do these Alivus Life Sciences figures come from?

From Alivus Life Sciences' own consolidated results filings to NSE, in ₹ crore as filed (Q2 FY27 on 29 October 2026). Growth compares the same consolidated figures a year and a quarter earlier.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.